Clinical Trials

NCT IdNCT04108104
TitleClinical Outcome of a Patented Pharmaceutical Composition (KT-110) to Treat Alcohol Use Disorder While Avoiding Major Side Effects
ConditionAlcohol Use Disorder
OrganizationKinnov Therapeutics
Sponsor/CollaboratorsKinnov Therapeutics
StatusNot yet recruiting
Older Adult
Location (with distance)
DescriptionDouble-blind randomised, parallel-group, three-arm, multicentre, placebo-controlled study The primary objective is to demonstrate the superiority of the combination of Periactine® (cyproheptadine 8 mg/day or 12 mg/day) and Alpress® (prazosin 5 mg/day or 10 mg/day) over placebo on the reduction of the total alcohol consumption (TAC), in alcohol-dependent patients. 180 patients will be randomised into the two treatment groups (N=60 in the low-dose group and N=60 in the high-dose group) and the placebo group (N=60).